Nanomedicines have been reported to attenuate POCD and AD by modulating the production, folding, aggregation and degradation of pathogenic Aβ.[205, 206, 207] For instance, owing to the higher affinity of graphene oxide nanosheets (GO) for Aβ precursor protein (APP) than for Aβ‐activating enzymes (BACE1), GO interfered with the co‐localization of APP and BACE1 and inhibited the β‐cleavage of APP by BACE1, thus decreasing Aβ production. This evidence concerns the gene APP and Alzheimer disease.